Enovis Co. (NYSE:ENOV) Receives $67.00 Consensus Price Target from Analysts

Shares of Enovis Co. (NYSE:ENOV) have received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $67.00.

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $65.00 price target on shares of Enovis in a research report on Thursday, November 7th. JMP Securities started coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price objective on the stock. Finally, Evercore ISI cut their price objective on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st.

Enovis Stock Down 2.0 %

Enovis stock opened at $44.87 on Thursday. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -20.49 and a beta of 1.94. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company’s 50-day moving average price is $45.83 and its two-hundred day moving average price is $44.33. Enovis has a 52 week low of $38.27 and a 52 week high of $65.03.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same quarter last year, the firm posted $0.56 EPS. The business’s revenue for the quarter was up 21.0% on a year-over-year basis. On average, analysts expect that Enovis will post 2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale bought a new stake in Enovis during the 3rd quarter worth about $55,000. Benjamin F. Edwards & Company Inc. raised its holdings in Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after purchasing an additional 371 shares during the last quarter. FMR LLC increased its stake in shares of Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after acquiring an additional 484 shares during the last quarter. Heritage Family Offices LLP bought a new stake in shares of Enovis in the 3rd quarter valued at about $206,000. Finally, XTX Topco Ltd bought a new stake in shares of Enovis in the 3rd quarter valued at about $217,000. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.